Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
Clinical trial NCT04140162 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04140162
- Sponsor
- University of Michigan Rogel Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-05
- Primary completion
- 2024-05-02
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.